Literature DB >> 19802973

Activity of ceftazidime and newer antibiotics against Gram-negative bacilli.

H H Schassan1, J Fedder.   

Abstract

Ceftazidime is a new parenterally applicable cephalosporin with high beta-lactamase stability and a remarkable activity against the Enterobacteriaceae and non-fermentative Gram-negative bacilli. The in-vitro activity of ceftazidime in general is comparable with that of cefotaxime and moxalactam. Ceftazidime proved the most active of the newer cephalosporins against Ps. aeruginosa, Ps. cepacia, Ser. marcescens and Pr. vulgaris. The bactericidal effectiveness of ceftazidime is excellent against the majority of species tested. Ceftazidime is a promising new beta-lactam antibiotic and the first clinical results seem to confirm the excellent in-vitro activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19802973     DOI: 10.1093/jac/8.suppl_b.79

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.

Authors:  J H Joshi; K A Newman; B W Brown; R S Finley; R L Ruxer; M A Moody; S C Schimpff
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

2.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

Review 3.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.